In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recentβ-lactam/β-lactamase inhibitor combinations
Anne Santerre Henriksen,Fabio Arena,Marie Attwood,Rafael Canton,Sören Gatermann,Thierry Naas,Ian Morrissey,Christopher Longshaw,Birgit Willinger,David Leyssene,Christian Cattoen,Corentine Alauzet,Pierre Boyer,Véronique Dubois,Katy Jeannot,Stephane Corvec,Alix Pantel,Thomas Guillard,Audrey Merens Gontier,Thierry Naas,Holger Rohde,Stefan Ziesing,Can Imirzalioglu,Klaus-Peter Hunfeld,Jette Jung,Sören Gatermann,Mathias Pletz,Gabriele Bianco,Anna Giammanco,Davide Carcione,Giammarco Raponi,Caterina Matinato,Enea Gino Di Domenico,Paolo Gaibani,Anna Marchese,Fabio Arena,Claudia Niccolai,Stefania Stefani,Cristina Pitart,Jose Luis Barrios,Emilia Cercenado,German Bou,Alicia Beteta Lopez,Rafael Canton,Jose Lopez Hontangas,Irene Gracia-Ahufinger,Antonio Oliver,Lorena Lopez-Cerero,Nieves Larrosa,David Wareham,John Perry,Anna Casey,Jasvir Nahl,Daniel Hughes,Michael Coyne,Michelle Lister,Marie Attwood,ARTEMIS Study Investigators
DOI: https://doi.org/10.1128/spectrum.04181-23
IF: 3.7
2024-06-22
Microbiology Spectrum
Abstract:ABSTRACT Carbapenem-resistant Enterobacterales represent a major health threat and have few approved therapeutic options. Enterobacterales isolates were collected from hospitalized inpatients from 49 sites in six European countries (1 January–31 December 2020) and underwent susceptibility testing to cefiderocol and β-lactam/β-lactamase inhibitor combinations. Meropenem-resistant (MIC >8 mg/L) and cefiderocol-susceptible isolates were analyzed by PCR, and cefiderocol-resistant isolates by whole-genome sequencing, to identify resistance mechanisms. Overall, 1,909 isolates (including 970 Klebsiella spp., 382 Escherichia coli , and 244 Enterobacter spp.) were collected, commonly from bloodstream infections (43.6%). Cefiderocol susceptibility was higher than approved β-lactam/β-lactamase inhibitor combinations and largely comparable to cefepime-taniborbactam and aztreonam-avibactam against all Enterobacterales (98.1% vs 78.1%–97.4% and 98.7%–99.1%, respectively) and Enterobacterales resistant to meropenem ( n = 148, including 125 Klebsiella spp.; 87.8% vs 0%–71.6% and 93.2%–98.6%, respectively), β-lactam/β-lactamase inhibitor combinations (66.7%–92.1% vs 0%–88.1% and 66.7%–97.9%, respectively), and to both meropenem and β-lactam/β-lactamase inhibitor combinations (61.9%–65.9% vs 0%–20.5% and 76.2%–97.7%, respectively). Susceptibilities to approved and developmental β-lactam/β-lactamase inhibitor combinations against cefiderocol-resistant Enterobacterales ( n = 37) were 10.8%–56.8% and 78.4%–94.6%, respectively. Most meropenem-resistant Enterobacterales harbored Klebsiella pneumoniae carbapenemase (110/148) genes, although metallo-β-lactamase (35/148) and oxacillinase (OXA) carbapenemase (6/148) genes were less common; cefiderocol susceptibility was retained in β-lactamase producers, other than NDM, AmpC, and non-carbapenemase OXA producers. Most cefiderocol-resistant Enterobacterales had multiple resistance mechanisms, including ≥1 iron uptake-related mutation (37/37), carbapenemase gene (33/37), and ftsI mutation (24/37). The susceptibility to cefiderocol was higher than approved β-lactam/β-lactamase inhibitor combinations against European Enterobacterales, including meropenem- and β-lactam/β-lactamase inhibitor combination-resistant isolates. IMPORTANCE This study collected a notably large number of Enterobacterales isolates from Europe, including meropenem- and β-lactam/β-lactamase inhibitor combination-resistant isolates against which the in vitro activities of cefiderocol and developmental β-lactam/β-lactamase inhibitor combinations were directly compared for the first time. The MIC breakpoint for high-dose meropenem was used to define meropenem resistance, so isolates that would remain meropenem resistant with doses clinically available to patients were included in the data. Susceptibility to cefiderocol, as a single active compound, was high against Enterobacterales and was higher than or comparable to available β-lactam/β-lactamase inhibitor combinations. These results provide insights into the treatment options for infections due to Enterobacterales with resistant phenotypes. Early susceptibility testing of cefiderocol in parallel with β-lactam/β-lactamase inhibitor combinations will allow patients to receive the most appropriate treatment option(s) available in a timely manner. This is particularly important when options are more limited, such as against metallo-β-lactamase-producing Enterobacterales.
microbiology